Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.

J Pediatr Endocrinol Metab

Department of Surgery, UCLA and Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7098, USA.

Published: November 2021

Objectives: The purpose of this study was to review our success rate performing the histrelin implant procedure in clinic without sedation.

Methods: A retrospective study was performed for histrelin implant procedures done at our institution from 2008 to 2020. Wilcoxon rank-sum test or Fisher's exact test was utilized to identify significant differences (p<0.05).

Results: A total of 73 patients underwent 184 histrelin implant procedures from 2008 to 2020. In the past few years, there has been a decrease in procedures for precocious puberty and an increase for gender dysphoria. The majority of procedures were performed in clinic without sedation (82%). The only risk factor associated with requiring sedation was younger age (median 9 vs. 10 years; p<0.003). Complications (i.e. implant fracture or need for counter-incision) were noted in 10 of the procedures (5%). The only risk factor identified for a procedural complication during implant removal/replacement was interval time from insertion (21 vs. 13 months; p<0.01). The only documented wound problem reported was dermatitis in 1 patient (no suture granuloma, dehiscence, or implant extravasation).

Conclusions: Procedural refinements and distraction therapy have enabled us to perform the majority of procedures in clinic without sedation. In our experience, procedural difficulty and complications appear to increase with prolonged implant duration. Histrelin implantation is increasingly being performed for gender dysphoria.

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem-2021-0432DOI Listing

Publication Analysis

Top Keywords

histrelin implant
8
optimizing pediatric
4
pediatric histrelin
4
histrelin implantation
4
implantation improve
4
improve success
4
success rates
4
rates clinic
4
clinic sedation
4
sedation objectives
4

Similar Publications

Introduction: Gonadotropin releasing hormone analogs (GnRHas) are used for treatment of precocious puberty. Over the last decade, several new formulations have been approved.

Methods: The Drugs and Therapeutics Subcommittee of the Pediatric Endocrine Society (PES) undertook a review to ascertain the current treatment options, prescribing behaviors, and practices of GnRHas among pediatric endocrinologists practicing within the USA.

View Article and Find Full Text PDF

Background: Fertility preservation (FP) is an important aspect of the care of transgender patients in whom Gender Affirming Medical Treatment (GAT) may begin before puberty is completed. While there are overall few studies that can be used to guide conversations about long-term effects of GAT, there are concerns that GAT could negatively impact fertility. Prior studies have shown low utilization of FP in this population, with avoidance of delay in starting GAT cited as one of the most common reasons for foregoing FP.

View Article and Find Full Text PDF

Trends in Histrelin Implantation at a Pediatric Tertiary Care Center.

J Surg Res

November 2023

The Children's Hospital of Philadelphia, Division of Pediatric General, Thoracic and Fetal Surgery, Philadelphia, Pennsylvania.

Introduction: Determine procedural outcomes and identify changing trends of utilization among patients undergoing histrelin implantation at a large pediatric tertiary care center over 15 y.

Methods: Retrospective review of all patients undergoing histrelin implantation between January 2008 and April 2022.

Results: A total of 746 patients underwent 1794 unique procedures (1364 placements/replacements, 430 removals).

View Article and Find Full Text PDF

Extended Use of Histrelin Implant in Pediatric Patients.

Transgend Health

June 2023

Division of Pediatric Endocrinology, Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, California, USA.

Purpose: Histrelin implant (HI) is a gonadotropin-releasing hormone agonist (GnRHa) used in pediatrics to treat central precocious puberty (CPP) and for pubertal suppression in transgender/non-binary (TG/NB) youth with gender dysphoria. HI is designed for annual removal/replacement; however, effectiveness has been reported beyond 1 year. No previous study has assessed prolonged HI use in TG/NB youth.

View Article and Find Full Text PDF

Objectives: The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a single histrelin implant for more than 12 months in children with CPP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!